SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2019 Financial Results
August 14, 2019 16:15 ET
|
SELLAS Life Sciences Group
- Multiple Clinical Milestones and Data Sets Expected by Year End / Q1 2020 - - Company to Host its First R&D Investor Day in Q4 2019 - NEW YORK, Aug. 14, 2019 (GLOBE NEWSWIRE) -- SELLAS...
SELLAS Announces Completion of Enrollment in Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast
August 05, 2019 08:30 ET
|
SELLAS Life Sciences Group
NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...
SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study
July 31, 2019 08:15 ET
|
SELLAS Life Sciences Group
- Study is Being Conducted with Merck Under a Clinical Trial Collaboration and Supply Agreement - - Trial to Enroll Patients with Ovarian, Colorectal, Triple Negative Breast, and Small Cell Lung...
SELLAS Life Sciences Announces Closing of $15 Million Public Offering
June 18, 2019 16:33 ET
|
SELLAS Life Sciences Group
NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or the “Company”), a late-stage biopharmaceutical company focused on the development of novel...
SELLAS Life Sciences Announces Pricing of $15 Million Public Offering
June 14, 2019 08:30 ET
|
SELLAS Life Sciences Group
NEW YORK, June 14, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical stage biopharmaceutical company focused on the development of novel...
SELLAS Announces Immune Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S (NPS) Plus Trastuzumab Presented at ASCO 2019
June 03, 2019 08:30 ET
|
SELLAS Life Sciences Group
NPS-Specific Cytotoxic T-Lymphocyte Mean Frequencies Increased by 2.86-fold Compared to Baseline at 30 months Notable Correlation Between Progressive Increase of NPS-Specific Cytotoxic T-Lymphocyte...
SELLAS Life Sciences Provides Business Update and Reports First Quarter 2019 Financial Results
May 15, 2019 16:30 ET
|
SELLAS Life Sciences Group
NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...
SELLAS Life Sciences Reports 2018 Financial Results and Provides Business Update
March 22, 2019 08:39 ET
|
SELLAS Life Sciences Group
NEW YORK, March 22, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of...
SELLAS Life Sciences Announces Presentation of Final Data Analysis from Phase 2b Study of Nelipepimut-S Plus Trastuzumab at the 2019 ASCO-SITC Clinical Immuno-Oncology Meeting
March 04, 2019 08:30 ET
|
SELLAS Life Sciences Group
NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of...
SELLAS Life Sciences Announces Review of Strategic Alternatives
February 26, 2019 08:30 ET
|
SELLAS Life Sciences Group
Phase 1/2 basket trial of lead clinical candidate, galinpepimut-S (GPS), plus Keytruda® (pembrolizumab) ongoing; Phase 3 registrational study for GPS monotherapy in acute myeloid leukemia (AML)...